KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash from Operations (2018 - 2025)

Adaptive Biotechnologies' Cash from Operations history spans 8 years, with the latest figure at 2055000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 116.45% year-over-year to 2055000.0; the TTM value through Dec 2025 reached 45986000.0, up 51.7%, while the annual FY2025 figure was 45986000.0, 51.7% up from the prior year.
  • Cash from Operations for Q4 2025 was 2055000.0 at Adaptive Biotechnologies, up from 7127000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 2055000.0 in Q4 2025 and bottomed at 64453000.0 in Q1 2022.
  • The 5-year median for Cash from Operations is 33616000.0 (2021), against an average of 33709700.0.
  • The largest annual shift saw Cash from Operations plummeted 84.28% in 2021 before it soared 116.45% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 53826000.0 in 2021, then surged by 44.23% to 30019000.0 in 2022, then rose by 10.28% to 26932000.0 in 2023, then skyrocketed by 53.62% to 12491000.0 in 2024, then skyrocketed by 116.45% to 2055000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Cash from Operations are 2055000.0 (Q4 2025), 7127000.0 (Q3 2025), and 12430000.0 (Q2 2025).